Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen.
Burke
George W
GW
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Highland Professional Building 5th Floor, 1801 NW 9th Avenue, Rm. 521, Miami, FL 33136, USA. gburke@med.miami.edu
Ciancio
G
G
Figueiro
J
J
Olson
L
L
Gomez
C
C
Rosen
A
A
Suzart
K
K
Miller
J
J
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000502:physiology*; D004359:Drug Therapy, Combination; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D008775:Methylprednisolone / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D009173:Mycophenolic Acid; D016559:Tacrolimus; D008775:Methylprednisolone